

3 August 2017

2017/18 Invitation to Tender

PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on:

- A proposal to tender certain pharmaceuticals for sole supply; and
- The draft process and terms and conditions for the 2017/18 Invitation to Tender (2017/18 Tender).

PHARMAC welcomes all feedback on the draft 2017/18 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC and would be considered by the PHARMAC Board (or its Delegate, where applicable) prior to making a decision on this proposal.

ALL RESPONSES ARE DUE BY 5 PM, FRIDAY 1 SEPTEMBER 2017

Feedback should be provided by submitting an email or letter to the Tender Analysts:

Email: tender@pharmac.govt.nz

Letter: Tender Analysts
PHARMAC
PO Box 10-254
Wellington 6143

DDI: Tim Nuthall: (04) 901 3233
Laura Baker (04) 916 7522

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

Details of the proposed 2017/18 Tender

In accordance with PHARMAC's objective (to secure, for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from

pharmaceutical treatment and from within the amount of funding provided), PHARMAC is consulting on a proposal to tender certain pharmaceuticals for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB hospital pharmacies.

Attached to this letter (as Schedule Two) is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply and/or Hospital Supply Status. Pharmaceuticals are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each pharmaceutical has a 'C' and/or 'H' next to it to indicate whether it is proposed to be tendered for community and/or hospital supply.

In general, the proposed 2017/18 Tender process would be similar to the 2016/17 Tender. A copy of the draft 2017/18 Invitation to Tender is available on our website: www.pharmac.health.nz, or by contacting PHARMAC.

We are seeking feedback on the approach outlined in the following pages, in particular on:

- The proposed tender process and timeline;
- The actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule Two, including the impact of a brand switch on patients and clinical staff; and
- For hospital pharmaceuticals, your views on the appropriate Discretionary Variance (DV) Limit for each pharmaceutical, in the event you consider a 1% DV Limit to be clinically unacceptable.

Background

Since 1997 PHARMAC has been using the strategy of tendering pharmaceuticals for sole supply of pharmaceuticals for a fixed period of time. Regular tendering has proven to be an effective way to encourage competition among suppliers of pharmaceuticals. As in the past, the community and hospital tender processes would be run in unison, however, the pharmaceutical list for community and hospital supply may be different.

Key Aspects of Awarding a Tender for Community Pharmaceuticals:

- For community pharmaceuticals, the tender winning brand would be the only subsidised brand for up to approximately 3 years. The Sole Subsidised Supply period would conclude on 30 June 2021 for all Tenders awarded from the 2017/18 Tender.
- No other brand of the pharmaceutical would be listed (or subsidised) in Section B of the Pharmaceutical Schedule during the Sole Subsidised Supply period.
- Other brands could continue to be marketed, sold and dispensed during the Sole Subsidised Supply Status period, but they would not receive a subsidy.
- Any pharmaceutical that currently carries a manufacturer's surcharge (that is, the additional patient charge above that of the patient co-payment) would become fully subsidised if a tender was awarded for that pharmaceutical.

Key Aspects of Awarding a Tender for DHB Hospital Pharmaceuticals:

- For DHB hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (subject to any allowance for alternative brands under the agreed DV Limits) for up to approximately 3 years. The Hospital Supply Status period would conclude on 30 June 2021 for all tenders awarded from the 2017/18 Tender.
- No other brand of the pharmaceutical would be listed in Section H of the Pharmaceutical Schedule during the Hospital Supply Status period.

Key Dates and Timeframes for the 2017/18 Tender:

The proposed timelines for the 2017/18 Tender are as follows:

Date	Event
3 August 2017	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
28 August 2017	Final date for receipt of Alternative Commercial Proposals (ACPs) to tendering by PHARMAC.
1 September 2017	Final date for all consultation to be received.
September 2017	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Factors for Consideration, and enters into provisional contracts with suppliers where appropriate.
September 2017	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
September/October 2017	Consultation and decisions on Alternative Commercial Proposals.
Early November 2017	Issuing of the 2016/17 Tender.
15 December 2017	Invitation to Tender closes.
From end of January 2018	Decisions on the first Tender winners announced.

Contractual obligations for suppliers

A copy of the draft terms and conditions which would form the terms of the 2017/18 Tender contract is available on the PHARMAC website: www.pharmac.health.nz.

Proposed inclusion of the following provisions in the 2017/18 Invitation to Tender

Matters for evaluation

Further information that will be considered in applying the Factors for Consideration by the Evaluation Committee when evaluating products included in the 2017/18 Tender will include;

- (i) alternative manufacturers of the finished product and active ingredients (if any); and
- (ii) other markets in which you currently supply the Pharmaceutical.

Tender Submission Form

PHARMAC propose to include a provision in the 2017/18 Tender relating to information that must be supplied regarding a Tender Item.

The provision will state that, as well as the existing information required to be submitted in the tender submission form, additional detail and information regarding pharmaceuticals which do not require consent from Medsafe will be required as follows;

- (i) Evidence and justification as to why Consent from Medsafe is not required for the Tender item(s);
- (ii) Confirmation that the Tender Items(s) you are submitting a Tender Bid in respect of meet the relevant standards and/or regulatory requirements for its intended use and details on what those standards and/or regulatory requirements are; and
- (iii) Details on the Tender Item(s) including excipients and shelf life.

In addition, further information regarding other markets in which the pharmaceutical or medical device is currently provided by you, may be included in the tender submission form at the supplier's discretion.

Price Change

PHARMAC propose to include a provision in the 2017/18 Tender that amends the terms and conditions relating to price changes in the event of award of a tender item for sole supply and/or hospital sole supply as follows. Where your brand of the pharmaceutical is currently listed on the Pharmaceutical Schedule, if the price would result in a price increase for your brand of the pharmaceutical you must supply the pharmaceutical at the new price from the 22nd day of the month prior to the start date, and the pharmaceutical will be subsidised at the new price from the start date (as defined in the 2017/18 Tender).

PCTs

PHARMAC propose to include a provision in the 2017/18 Tender relating to a preference for PCT products that have post-compounding stability data greater than 48 hours.

Stock Reporting

PHARMAC proposes the inclusion of a provision in the 2017/18 Tender relating to a supplier providing reports to PHARMAC on pharmaceutical stock levels upon PHARMAC's request during the sole supply and/or hospital supply status periods.

Additional Special Terms

PHARMAC proposes to include a new schedule in the 2017/18 Tender relating to special terms for the supply of somatropin as follows.

A tenderer who submits a tender bid for somatropin, should note that special terms will also apply to the supply of somatropin. In this respect, successful tenderers shall provide the following resources and related products at no cost:

- The provision of education, training and support Resources to endocrinologists, paediatric endocrinologists, pharmacies and patients in respect of the use of somatropin.
- The Resources shall be provided to all endocrinologists, paediatric endocrinologists, pharmacies and patients in New Zealand or upon request by any relevant party.

- The Resources shall be provided to patients when their prescription is filled and directly to all endocrinologists, paediatric endocrinologists and pharmacies before the commencement of any sole supply period.
- The provision of Related Products for your proposed brand of somatropin for the benefit of patients, in respect of the use of somatropin. The Related Products shall be delivered to the nominated delivery address of the prescribed patient.

For the purposes of this paragraph:

“Resources” shall include but not be limited to the:

- provision of patient training and medical education and support for endocrinologists, paediatric endocrinologists and pharmacies on the use of somatropin devices, including a preference for clinical educators to talk specifically with patients and for an 0800 number to be available for patients to contact with any further queries;
- provision of training materials (DVDs, pamphlets, leaflets, brochures) to new patients; and
- provision of presentations and/or demonstrations on the use of somatropin devices to patients and/or healthcare professionals.

“Related Products”, which shall be inclusive of the replacement of any defective Related Product, shall include but not be limited to devices, needles, needle clippers, sharps bins, vials and other products which are required for the safe treatment of your brand of somatropin.

PHARMAC may request tenderers to provide a proposal and evidence of the Resources and Related Products after the submission of a tender bid for somatropin

Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from the 2015/16 Tender and the 2016/17 Tender prior to issuing the 2017/18 Tender, and may close the tender for some of these items, and reissue them as part of the 2017/18 tender. The following Tender Bids remain unresolved, and may potentially be added to the 2017/18 Tender following consultation:

2015/16 Invitation to Tender

Chemical Name	Line Item
Atomoxetine	Cap 10 mg
Atomoxetine	Cap 100 mg
Atomoxetine	Cap 18 mg
Atomoxetine	Cap 25 mg
Atomoxetine	Cap 40 mg
Atomoxetine	Cap 60 mg
Atomoxetine	Cap 80 mg
Clonazepam	Tab 2 mg
Clonazepam	Tab 500 mcg
Cytarabine	Inj 1 g
Cytarabine	Inj 2 g
Pemetrexed	Powder for infusion, 100 mg
Pemetrexed	Powder for infusion, 500 mg
Salbutamol	Oral liq 2 mg per 5 ml
Tamsulosin	Tab 400 mcg

2016/17 Invitation to Tender

Chemical Name	Line Item
Adapalene	Crm 0.1%
Adapalene	Gel 0.1%
Albendazole	Tab 200 mg
Amantadine hydrochloride	Cap 100 mg
Beclomethasone Dipropionate	Metered aqueous nasal spray, 100 mcg per dose
Beclomethasone Dipropionate	Metered aqueous nasal spray, 50 mcg per dose
Benzylpenicillin Sodium [Penicillin G]	Inj 3 g
Brinzolamide	Eye drops 1%
Budesonide	Metered aqueous nasal spray, 100 mcg per dose
Budesonide	Metered aqueous nasal spray, 50 mcg per dose

Chemical Name	Line Item
Bupivacaine hydrochloride with adrenaline	Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml sterile pack
Bupivacaine hydrochloride with adrenaline	Inj 5 mg per ml with adrenaline 1:200,000, 20 ml sterile pack
Buprenorphine with Naloxone	Tab sublingual 2 mg with naloxone 0.5 mg
Buprenorphine with Naloxone	Tab sublingual 8 mg with naloxone 2 mg
Calcipotriol	Soln 50 mcg per ml (pack size 30 ml or greater)
Calcium folinate	Inj 1g
Calcium folinate	Inj 100 mg
Calcium folinate	Inj 50 mg
Caspofungin	Inj 50 mg
Caspofungin	Inj 70 mg

Chemical Name	Line Item
Cetirizine hydrochloride	Oral liq 1 mg per ml
Cetrimide	Solution 20% (pack size of 100 ml or less)
Chlorhexidine with ethanol	Soln 2% with ethanol 70%, non-staining (pink) 100 ml
Chlorhexidine with ethanol	Soln 2% with ethanol 70%, non-staining pink (pack size less than 50 ml)
Chlorhexidine with ethanol	Soln 2% with ethanol 70%, staining (red) 100 ml
Chlorhexidine with ethanol	Soln 2% with ethanol 70%, staining red (pack size less than 50 ml)
Ciprofloxacin (current access)	Eye drops 0.3%
Ciprofloxacin (widened access)	Eye drops 0.3%
Colestimethate	Inj 150 mg
Ephedrine	Inj 3 mg per ml, 10 ml prefilled syringe
Gemcitabine hydrochloride	Inj 1 g
Gemcitabine hydrochloride	Inj 200 mg
Granisetron	Inj 1 mg per ml
Hyoscine N-buylbromide	Inj 20 mg, 1 ml
Imiquimod	Crm 5%
Lamivudine	Oral liq 5 mg per ml
Lamivudine	Tab 100 mg
Levodopa with Carbidopa	Tab 100 mg with carbidopa 25 mg
Levodopa with Carbidopa	Tab 250 mg with carbidopa 25 mg
Levodopa with Carbidopa	Tab long-acting 200 mg with carbidopa 50 mg
Lidocaine [Lignocaine] Hydrochloride	Inj 1%, 20 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 1 %, 5 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 2%, 20 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 2%, 5 ml
Lidocaine [Lignocaine] Hydrochloride	Spray – 10 mg dose per spray
Losartan with hydrochlorothiazide	Tab 50 mg with hydrochlorothiazide 12.5 mg

Chemical Name	Line Item
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride -	Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg
Mebeverine hydrochloride	Tab 135 mg
Mercaptopurine	Tab 50 mg
Meropenem	Inj 1 g
Meropenem	Inj 500 mg
Methylphenidate Hydrochloride	Tab immediate-release 10 mg
Methylphenidate Hydrochloride	Tab immediate-release 20 mg
Methylphenidate Hydrochloride	Tab immediate-release 5 mg
Methylphenidate Hydrochloride	Tab sustained-release 20 mg
Metoclopramide hydrochloride	Inj 5 mg per ml, 2 ml ampoule
Minocycline hydrochloride	Cap 100 mg
Minocycline hydrochloride	Tab 50 mg
Moxifloxacin	Tab 400 mg
Nitrofurantoin	Tab 100 mg
Nitrofurantoin	Tab 50 mg
Nitrofurantoin	Tab modified-release 100 mg
Ondansetron	Tab disp 4 mg
Ondansetron	Tab disp 8 mg
Paraffin (current access)	White soft – 500g
Paraffin (widened access)	White soft – 500 g
Pregnancy tests	HCG urine – Pregnancy test – HCG urine – Dipstick
Pregnancy tests	HCG urine – Pregnancy test – HCG urine – Cassette
Pregnancy tests	HCG urine – Pregnancy test – HCG urine – Midstream
Ribavirin	Tab 200 mg
Ribavirin	Tab 400 mg
Ribavirin	Tab 600 mg
Tamoxifen citrate	Tab 10 mg
Tamoxifen citrate	Tab 20 mg
Tenoxicam	Inj 20 mg
Tetracaine [amethocaine]	Gel 4%

Chemical Name	Line Item
hydrochloride	
Thiamine hydrochloride	Tab 50 mg
Tigecycline	Inj 50 mg
Trimethoprim with sulphamethoxazole [Co-trimoxazole]	Inj 16 with sulphamethoxazole 80 mg per ml, 5 ml
Zinc	Paste (pack size 50 g or less)

Chemical Name	Line Item
Zinc and castor Oil	Oint 5% or less (pack size greater than 30 g)
Zinc and castor Oil	Oint BP (pack size greater than 30 g)
Zinc sulphate	Cap 50 g elemental
Zolmitriptan	Nasal Spray

Should any unresolved Tender Bids be declined prior to the release of the 2017/18 Tender, PHARMAC would consider including those pharmaceuticals in the 2017/18 Tender. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out in Schedule Two.

Distribution of Consultation Documents

Although this consultation letter has been widely distributed, should you consider that a particular person, group or agency should receive this letter and/or future tender documents, please feel free to contact PHARMAC or refer it on directly (note, all tender documents and consultations are also available from our website at www.pharmac.health.nz/news/consultation). We also invite any person or group to contact PHARMAC should you wish to meet to discuss the proposals contained in this consultation letter.

Schedule Two: Possible pharmaceuticals for tender for sole supply

Order of pharmaceuticals in this Schedule

Pharmaceuticals have been listed in groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of these groups, and the corresponding page numbers for your ease of reference. Pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one group.

Therapeutic Group	Page Numbers
Alimentary Tract and Metabolism	10
Blood and Blood Forming Organs	11 - 12
Cardiovascular System	12 – 15
Dermatologicals	15 – 17
Genito-Urinary System	17 – 18
Hormone Preparations – Systemic excluding contraceptives	18 - 19
Infections – Agents for Systemic Use	19 – 21
Musculoskeletal System	22
Nervous System	22 – 26
Oncology and Immunosuppressants	26 – 28
Respiratory System and Allergies	28
Sensory Organs	28 – 29
Various	29

Information provided for each pharmaceutical

For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information:

- the current ex-manufacturer subsidy per unit of measure as at 1 July 2017
- the number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2016
- an estimate of the annual community market value at current subsidies (estimated by multiplying the volume of units subsidised in the year ending 30 June 2016 by the relevant listed unit subsidy as at 1 July 2016); and
- comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.

Explanation of terms, symbols and abbreviations

Most terms and abbreviations used are self-explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

The following table explains the symbols used in the draft pharmaceutical list:

Symbol	Explanation
Underlined	Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2018 unless otherwise stated in the Comments column and a listing of a new brand could only occur after that date.
C	To be tendered for Sole Subsidised Supply Status (community pharmaceuticals).
H	To be tendered for Hospital Supply Status (DHB hospital pharmaceuticals).
PCT	A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project.
+	PHARMAC has been advised of the existence of a patent.
*	There is no fully funded product available for this line item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP) means a Pharmaceutical, marked with an “@”, for which the supplier of the successful Tender Bid would be required to hold additional stock.
#	A rebate currently exists.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Acarbose					
Tab 50 mg	1,704,350	\$81,059	\$0.0476	C H 1%	
Tab 100 mg	1,024,706	\$88,576	\$0.0864	C H 1%	
Alpha Tocopheryl Acetate					
Oral liq 156 u per ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Bisacodyl					
Suppos 10 mg	251,246	\$94,971	\$0.3780	C H 1%	
Tab 5 mg	1,488,517	\$44,581	\$0.0300	C H 1%	
Budesonide					
Cap 3 mg modified release	239,910	\$443,833	\$1.8500	C H 1%	Special Authority restrictions may apply.
Calcium Carbonate					
Oral liq 250 mg per ml (100 mg elemental per ml)	17,665	\$1,378	\$0.0780	C H 1%	
Tab eff 0.875 - 1.75 g (0.5 g - 1 g elemental)	367,468	\$76,066	\$0.2070	C H 1%	Tab eff 1.75 g is currently listed on the Pharmaceutical Schedule. Units shown are for tab eff 1.75 g.
Chlorhexidine gluconate					
Mouthwash 0.2%	5,049,600	\$64,887	\$0.0129	C H 1%	
Docusate Sodium with Sennosides					
Tab 50 mg with total sennosides 8 mg	53,279,002	\$1,172,138	\$0.0220	C H 1%	
Ferrous Fumarate					
Tab 200 mg	12,922,945	\$373,473	\$0.0289	C H 1%	
Ferrous Fumarate with Folic Acid					
Tab 310 mg with folic acid 350 mcg	1,317,431	\$104,301	\$0.0792	C H 1%	
Ferrous Gluconate with Ascorbic Acid					
Tab 170 mg with ascorbic acid 40 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Ferrous Sulphate					
Tab long-acting 325 mg	8,714,167	\$598,402	\$0.0687	C H 1%	
Ferrous Sulphate with Ascorbic Acid					
Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg				C H 1%	Not currently listed in Schedule B of the Pharmaceutical Schedule.
Ferrous Sulphate with Folic Acid					
Tab long-acting 325 mg with folic acid 350 mcg	255,644	\$15,339	\$0.0600 *	C H 1%	
Glibenclamide					
Tab 5 mg	666,180	\$33,309	\$0.0500	C H 1%	
Glipizide					
Tab 5 mg	14,464,530	\$412,239	\$0.0285	C H 1%	
Glucose [Dextrose]					
Gel 40%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Tab 1.5 g				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Tab 3.1 g				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Tab 4 g				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Glycerol					
Suppos greater than 3 g	302,029	\$98,159	\$0.3250	C H 1%	
Glyceryl Trinitrate					
Oint 0.2%	168,240	\$123,375	\$0.7333	C H 1%	Special Authority restrictions may apply.
Hydrocortisone Acetate					
Rectal foam 10%. CFC-free	189,394	\$238,312	\$1.2583	C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Hydroxocobalamin					
<u>Inj 1 mg per ml, 1 ml</u>	325,009	\$250,257	\$0.7700	C H 1%	A 10% strength variance (plus or minus) would be considered.
Lansoprazole					
<u>Cap 15 mg</u>	1,407,749	\$71,514	\$0.0508	C H 1%	
<u>Cap 30 mg</u>	3,383,648	\$200,650	\$0.0593	C H 1%	
Macrogol 3350					
Powder for oral soln				C H 1%	Not currently listed on the Pharmaceutical Schedule. Note this is an electrolyte free presentation.
Metformin Hydrochloride					
<u>Tab immediate-release 500 mg</u>	129,341,383	\$1,240,384	\$0.0096	C H 1%	
<u>Tab immediate-release 850 mg</u>	14,939,704	\$233,657	\$0.0156	C H 1%	
<u>Tab immediate-release 1 g</u>				C H 1%	Not currently listed on the Pharmaceutical Schedule.
Miconazole					
<u>Oral gel 20 mg per g</u>	473,200	\$56,666	\$0.1198	C H 1%	Preference for a product that includes an appropriate measuring device
Pancreatic enzyme					
<u>Cap EC 20,000-25,000 BP u lipase, 12,000-18,000 BP u amylase and 900-1,100 BP u protease</u>	2,557,636	\$2,413,897	\$0.9438	C H 1%	
<u>Cap EC 9,000 -11,000BP u lipase, 8,000-10,000 BP u amylase and 150-500 BP u protease</u>	2,226,414	\$777,686	\$0.3493	C H 1%	
Pioglitazone					
<u>Tab 15 mg</u>	402,240	\$15,510	\$0.0386	C H 1%	
<u>Tab 30 mg</u>	331,555	\$18,640	\$0.0562	C H 1%	
<u>Tab 45 mg</u>	223,483	\$17,631	\$0.0789	C H 1%	

Blood and Blood Forming Organs

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Dextrose with Electrolytes					
Oral soln with electrolytes	24,932,000	\$163,305	\$0.0066	C H 1%	
Eptifibatide					
<u>Inj 0.75 mg per ml, 100 ml</u>				H 1%	
<u>Inj 2 mg per ml, 10 ml</u>				H 1%	
Filgrastim					
<u>Inj 300 mcg per ml, 0.5 ml prefilled syringe</u>	10,897	\$588,438	\$54.0000 #	C H 1%	There may be longer transition periods for this product. A confidential rebate applies.
<u>Inj 480 mcg per ml, 0.5 ml prefilled syringe</u>	3,354	\$289,786	\$86.4000 #	C H 1%	There may be longer transition periods for this product. A confidential rebate applies.
Folic Acid					
<u>Tab 0.8 mg</u>	6,392,081	\$131,677	\$0.0206	C H 1%	
<u>Tab 5 mg</u>	5,296,710	\$115,680	\$0.0218	C H 1%	
Pegfilgrastim					
<u>Inj 6 mg per 0.6 ml prefilled syringe</u>	5,889	\$6,360,120	\$1,080.0000 #	C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Potassium Chloride					
<u>Tab long-acting 600 mg</u>	6,831,260	\$253,440	\$0.0371	C H 1%	
Potassium dihydrogen phosphate					
<u>Inj 1 mmol per ml, 10 ml</u>				H 1%	
Sodium chloride					
<u>inj 0.9%, 10 ml, prefilled syringe</u>				H 1%	For use in flushing of in-situ vascular access devices only.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Blood and Blood Forming Organs

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Sodium chloride					
inj 0.9%, 3 ml, prefilled syringe				H 1%	For use in flushing of in-situ vascular access devices only.
inj 0.9%, 5 ml, prefilled syringe				H 1%	For use in flushing of in-situ vascular access devices only.
Sodium dihydrogen phosphate					
Inj 1 mmol per ml, 20 ml ampoule				H 1%	
Sodium polystyrene sulphonate					
<u>Powder</u>	262,866	\$49,011	\$0.1865	C H 1%	Preference for a measuring device to be included.
Ticagrelor					
Tab 90 mg	2,658,013	\$4,271,799	\$1.6071	+ C H 1%	Special Authority restrictions may apply.
Tranexamic Acid					
Inj 100 mg per ml, 5 ml - 10 ml				H 1%	

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Alprostadil					
Inj 0.5 mg per ml, 1 ml				H 1%	
Ambrisentan					
Tab 10 mg	3,150	\$481,425	\$152.8333 #	C H 1%	A confidential rebate applies. Longer transition periods may apply to this product. Special Authority restrictions may apply.
Tab 5 mg	1,289	\$197,002	\$152.8333 #	C H 1%	A confidential rebate applies. Longer transition periods may apply to this product. Special Authority restrictions may apply.
Amiloride					
Tab 5 mg	90,471	\$13,571	\$0.1500	C H 1%	
Atenolol					
<u>Tab 50 mg</u>	3,749,451	\$34,570	\$0.0092	C H 1%	
<u>Tab 100 mg</u>	1,409,349	\$21,619	\$0.0153	C H 1%	
Atorvastatin					
<u>Tab 10 mg</u>	19,612,874	\$364,407	\$0.0186	C H 1%	
<u>Tab 20 mg</u>	38,333,624	\$1,021,208	\$0.0266	C H 1%	
<u>Tab 40 mg</u>	38,852,267	\$1,649,667	\$0.0425	C H 1%	
<u>Tab 80 mg</u>	10,757,101	\$780,105	\$0.0725	C H 1%	
Atropine sulphate					
Inj 600 mcg, 1 ml	42,698	\$60,631	\$1.4200	C H 1%	There may be a preference for a smaller pack size.
Bezafibrate					
<u>Tab 200 mg</u>	668,848	\$67,259	\$0.1006	C H 1%	
<u>Tab long-acting 400 mg</u>	3,647,791	\$824,401	\$0.2260	C H 1%	
Bosentan					
<u>Tab 125 mg</u>	31,448	\$210,589	\$6.6964	C H 1%	Longer transition periods may apply to this product.
<u>Tab 62.5 mg</u>	12,315	\$82,467	\$6.6964	C H 1%	Longer transition periods may apply to this product.
Bumetanide					
Inj 500 mcg per ml, 4 ml			\$1.5900	C H 1%	
Tab 1 mg	2,419,716	\$395,866	\$0.1636	C H 1%	
Candesartan (current access)					
Tab 16 mg	7,770,981	\$528,427	\$0.0680	C H 1%	PHARMAC would only award a tender for either current access or widened access.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Candesartan (current access)					
Tab 32 mg	5,002,927	\$592,547	\$0.1184	C H 1%	PHARMAC would only award a tender for either current access or widened access.
Tab 4 mg	4,574,702	\$127,085	\$0.0278	C H 1%	PHARMAC would only award a tender for either current access or widened access.
Tab 8 mg	7,594,306	\$310,531	\$0.0409	C H 1%	PHARMAC would only award a tender for either current access or widened access.
Candesartan (widened access)					
Tab 16 mg				C H 1%	PHARMAC would only award a tender for either current access or widened access. Widened access would involve removal of the Special Authority restrictions.
Tab 32 mg				C H 1%	PHARMAC would only award a tender for either current access or widened access. Widened access would involve removal of the Special Authority restrictions.
Tab 4 mg				C H 1%	PHARMAC would only award a tender for either current access or widened access. Widened access would involve removal of the Special Authority restrictions.
Tab 8 mg				C H 1%	PHARMAC would only award a tender for either current access or widened access. Widened access would involve removal of the Special Authority restrictions.
Clonidine					
Inj 150 mcg per ml, 1 ml	13,019	\$41,843	\$3.2140	C H 1%	
<u>Tab 25 mcg</u>	3,317,446	\$311,906	\$0.0940	C H 1%	
Tab 150 mcg	554,878	\$190,434	\$0.3432	C H 1%	
Diltiazem Hydrochloride					
Inj 5 mg per ml, 5 ml				H 5%	
Tab 30 mg	578,660	\$26,618	\$0.0460	C H 5%	
Tab 60 mg	286,735	\$24,372	\$0.0850	C H 5%	
Cap long-acting 120 mg	7,941,117	\$505,594	\$0.0637	C H 5%	More than one brand is currently listed in the Pharmaceutical Schedule. Unit subsidy shown as the average unit subsidy of the products listed in the 2017 FYR.
Cap long-acting 180 mg	6,285,352	\$604,018	\$0.0961	C H 5%	More than one brand is currently listed in the Pharmaceutical Schedule. Unit subsidy shown as the average unit subsidy of the products listed in the 2017 FYR.
Cap long-acting 240 mg	4,764,343	\$612,199	\$0.1285	C H 5%	More than one brand is currently listed in the Pharmaceutical Schedule. Unit subsidy shown as the average unit subsidy of the products listed in the 2017 FYR.
Dobutamine					
Inj 12.5 mg per ml, 20 ml				H 1%	
Dopamine					
Inj 40 mg per ml, 5 ml				H 1%	
Enalapril					
<u>Tab 5 mg</u>	2,652,511	\$25,464	\$0.0096	C H 1%	
<u>Tab 10 mg</u>	2,814,508	\$34,900	\$0.0124	C H 1%	
<u>Tab 20 mg</u>	3,447,072	\$61,358	\$0.0178	C H 1%	
Eplerenone					
Tab 25 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule. Special Authority restrictions may apply.
Tab 50 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule. Special Authority restrictions may apply.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Epoprostenol					
Inj 0.5 mg vial				H 1%	Restrictions may apply.
Inj 1.5 mg vial				H 1%	Restrictions may apply.
Felodipine					
<u>Tab long-acting 2.5 mg</u>	11,499,129	\$555,753	\$0.0483	C H 1%	
<u>Tab long-acting 5 mg</u>	16,776,621	\$866,848	\$0.0517	C H 1%	
<u>Tab long-acting 10 mg</u>	11,727,820	\$899,172	\$0.0767	C H 1%	
Flecainide Acetate					
Cap long-acting 100 mg	885,798	\$1,150,058	\$1.2983	C H 1%	Longer transition timeframes may apply.
Cap long-acting 200 mg	860,602	\$1,973,076	\$2.2927	C H 1%	Longer transition timeframes may apply.
Inj 10 mg per ml, 15 ml	30	\$315	\$10.4900	C H 1%	
Tab 50 mg	451,236	\$292,929	\$0.6492	C H 1%	Longer transition timeframes may apply.
Furosemide					
Tab 20 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
<u>Tab 40 mg</u>	34,140,323	\$273,123	\$0.0080	C H 1%	
<u>Tab 500 mg</u>	322,414	\$161,207	\$0.5000	C H 1%	
Glyceryl trinitrate					
Inj 1 mg per ml, 5 ml				H 1%	
Inj 1 mg per ml, 50 ml				H 1%	
Inj 5 mg per ml, 10 ml				H 1%	
Lisinopril					
<u>Tab 5 mg</u>	1,329,044	\$26,581	\$0.0200	C H 1%	
<u>Tab 10 mg</u>	1,608,925	\$36,651	\$0.0228	C H 1%	
<u>Tab 20 mg</u>	2,183,947	\$66,982	\$0.0307	C H 1%	
Metaraminol Tartrate					
Inj 0.5 mg per ml, 20 ml prefilled syringe				H 1%	
Inj 1 mg per ml, 1 ml				H 1%	
Inj 1 mg per ml, 10 ml prefilled syringe				H 1%	
Inj 10 mg per ml, 1 ml				H 1%	
Metoprolol Tartrate					
<u>Tab 100 mg</u>	169,566	\$17,211	\$0.1015	C H 1%	
<u>Tab 50 mg</u>	681,290	\$31,612	\$0.0464	C H 1%	
Tab long-acting 200 mg	88,860	\$74,261	\$0.8357	C H 1%	
Milrinone					
Inj 1 mg per ml, 10 ml				H 1%	
Nadolol					
<u>Tab 40 mg</u>	1,914,996	\$307,357	\$0.1605	C H 1%	
<u>Tab 80 mg</u>	501,011	\$123,750	\$0.2470	C H 1%	
Noradrenaline					
Inj 0.06 mg per ml, 100 ml bag				H 1%	
Inj 0.06 mg per ml, 50 ml syringe				H 1%	
Inj 0.1 mg per ml, 100 ml bag				H 1%	
Inj 0.12 mg per ml, 100 ml bag				H 1%	
Inj 0.12 mg per ml, 50 ml syringe				H 1%	
Inj 0.16 mg per ml, 50 ml syringe				H 1%	
Inj 1 mg per ml, 100 ml bag				H 1%	
Pindolol					
Tab 5 mg	97,403	\$9,468	\$0.0972	C H 1%	
Tab 10 mg	113,584	\$17,742	\$0.1562	C H 1%	
Tab 15 mg	57,739	\$13,546	\$0.2346	C H 1%	
Propranolol					
Tab 10 mg	3,093,092	\$112,898	\$0.0365	C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Propranolol						
Tab 40 mg	2,574,978	\$119,736	\$0.0465	C H	1%	
Quinapril						
Tab 5 mg	6,991,831	\$334,839	\$0.0479	C H	1%	
Tab 10 mg	11,681,713	\$408,860	\$0.0350	C H	1%	
Tab 20 mg	20,186,753	\$1,338,987	\$0.0663	C H	1%	
Quinapril with Hydrochlorothiazide						
Tab 10 mg with hydrochlorothiazide 12.5 mg	2,423,916	\$294,918	\$0.1217	C H	1%	
Tab 20 mg with hydrochlorothiazide 12.5 mg	6,877,500	\$1,095,792	\$0.1593	C H	1%	
Ramipril						
Cap 1.25 mg				C H	1% Not currently listed on the Pharmaceutical Schedule.	
Cap 10 mg				C H	1% Not currently listed on the Pharmaceutical Schedule.	
Cap 2.5 mg				C H	1% Not currently listed on the Pharmaceutical Schedule.	
Cap 5 mg				C H	1% Not currently listed on the Pharmaceutical Schedule.	
Sildenafil						
Tab 100 mg	8,699	\$5,980	\$0.6875	C H	1%	
Tab 25 mg	80,294	\$15,055	\$0.1875	C H	1%	
Tab 50 mg	163,608	\$30,677	\$0.1875	C H	1%	
Sotalol						
Inj 10 mg per ml, 4 ml	150	\$1,962	\$13.0780	C H	1%	

Dermatologicals

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Aqueous Cream						
Crn (100 g or less)				H	1% Preference for tubes. Preference for sodium lauryl sulphate (SLS)-free presentation.	
Crn (greater than 100 g)	79,094,351	\$314,796	\$0.0040	C H	1% Preference for sodium lauryl sulphate (SLS)-free presentation.	
Benzoyl peroxide						
Soln/Gel 5%				C H	1% PHARMAC would accept a bid for either a solution or a gel. Not currently listed in Section B of the Pharmaceutical Schedule.	
Betamethasone Dipropionate With Calcipotriol						
Gel 500 mcg with calcipotriol 50 mcg per g	1,523,670	\$1,326,614	\$0.8707	C H	1%	
Oint 500 mcg with calcipotriol 50 mcg per g	2,418,900	\$2,106,064	\$0.8707	C H	1%	
Betamethasone Valerate						
Crn 0.1%	7,081,900	\$446,160	\$0.0630	C H	1%	
Lotn 0.1%	421,900	\$84,802	\$0.2010	C H	1%	
Oint 0.1%	2,249,300	\$141,706	\$0.0630	C H	1%	
Scalp app 0.1%	3,316,900			C H	1%	
Calamine						
Crn, aqueous, BP	3,256,336	\$48,519	\$0.0149	C H	1% Preference for a 100 g pack or similar.	
Lotn, BP	3,767,405	\$24,375	\$0.0065	C H	1% Preference for a 2000 ml pack or similar.	
Cetomacrogol						
Crn BP	89,294,067	\$489,331	\$0.0055	C H	1%	
Crn BP [100 g or less]				H	1% Preference for a product supplied in a tube.	
Chlorhexidine gluconate						
Handrub 1% with ethanol 70%	2,360,000	\$20,249	\$0.0086	C H	1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Dermatologicals

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Chlorhexidine gluconate					
<u>Soln 4%</u>	2,065,499	\$16,441	\$0.0080	C H 1%	500mL pump preferred
Ciclopirox olamine					
<u>Nail lacquer 8%</u>	172,228	\$159,926	\$0.9286	C H 1%	
Crotamiton					
<u>Crn 10%</u>	772,400	\$130,149	\$0.1685	C H 1%	
Dimethicone					
Crn 10%	1,211,500	\$11,873	\$0.0098	C H 1%	500 ml pump preferred.
Econazole Nitrate					
Crn 1%	24,100	\$1,205	\$0.0500	C H 1%	
Fluorouracil sodium					
<u>Crn 5%</u>	1,126,260	\$504,001	\$0.4475	C H 1%	
Fusidic acid					
Crn 2 %	680,655	\$114,350	\$0.1680	C H 1%	Preference for a pack size of 10 g or less.
Oint 2 %	2,129,340	\$489,748	\$0.2300	C H 1%	Preference for a pack size of 10 g or less.
Hydrocortisone					
Oint 1% (pack size 100 g or less)				C H 1%	Not currently listed in the Pharmaceutical Schedule.
<u>Oint 1% (pack size greater than 100 g)</u>				C H 1%	Not currently listed in the Pharmaceutical Schedule.
Hydrocortisone Butyrate					
Lipocream 0.1% (pack size 30 g or less)	21,663,020	\$1,660,904	\$0.0767	C H 1%	
Lipocream 0.1% (pack size greater than 30 g)	21,663,020	\$14,858,665	\$0.6859	C H 1%	
Milky Emulsion 0.1%	1,483,500	\$101,620	\$0.0685	C H 1%	
Oint 0.1%	2,939,500	\$201,356	\$0.0685	C H 1%	
Scalp lotn 0.1%	3,708,100	\$135,346	\$0.0365	C H 1%	
Hydrocortisone with Miconazole					
<u>Crn 1% with miconazole nitrate 2%</u>	5,467,095	\$728,928	\$0.1333	C H 1%	Preference for packsize 15g-30g
Hydrogen Peroxide					
Crn 1%	1,502,925	\$857,674	\$0.5707 #	C H 1%	Preference for a pack size of 50 g or more.
Crn 2%				C H 1%	Not currently listed on the Pharmaceutical Schedule. Preference for a pack size of 50 g or more.
<u>Soln 3% (10 vol)</u>				H 1%	Preference for pack size <200mL
Isotretinoin					
Cap 5 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions. Preference for a blister pack.
Cap 10 mg	1,745,059	\$217,609	\$0.1247	C H 1%	Patient/Clinician information on appropriate use should be available on a supplier's website. Preference for a blister pack.
Cap 20 mg	959,596	\$184,909	\$0.1927	C H 1%	Patient/Clinician information on appropriate use should be available on a supplier's website. Preference for a blister pack.
Liquid paraffin with white soft paraffin					
Liquid paraffin 50% with white soft paraffin 50% ointment (pack size 100 g or less)				C H 1%	Not currently listed in the Pharmaceutical Schedule.
Liquid paraffin 50% with white soft paraffin 50% ointment (pack size greater than 100 g)				C H 1%	Not currently listed in the Pharmaceutical Schedule.
Metronidazole					
Gel 0.75%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Indicated for fungating wounds or bacterial vaginosis.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Dermatologicals

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Mometasone furoate					
<u>Cr</u> m 0.1% (pack size 30 g or less)	220,228	\$22,177	\$0.1007	C H 1%	
<u>Cr</u> m 0.1% (pack size greater than 30 g)	2,532,619	\$146,892	\$0.0580	C H 1%	
<u>Lot</u> n 0.1% (pack size 30 ml or less)	338,647	\$82,969	\$0.2450	C H 1%	
<u>Oint</u> 0.1% (pack size 30 g or less)	136,582	\$13,754	\$0.1007	C H 1%	
<u>Oint</u> 0.1% (pack size greater than 30 g)	2,139,781	\$124,107	\$0.0580	C H 1%	
Mupirocin					
<u>Oint</u> 2%	181,305	\$79,774	\$0.4400 *	C H 1%	Any agreement may be subject to Special Authority restriction. Preference for a pack size of less than 10 g.
Oil in Water Emulsion (pack size 100 g or less)					
<u>Cr</u> m				C H 1%	Not currently listed in the Pharmaceutical Schedule.
Oil in Water Emulsion (pack size greater than 100 g)					
<u>Cr</u> m	102,427,155	\$460,922	\$0.0045	C H 1%	
Paraffin					
White soft (pack size 100 g or less)				H 1%	
Povidone Iodine					
Antiseptic soln 10% (pack size 15 ml or less)			\$0.0127 *	C H 1%	
Antiseptic soln 10% (pack size greater than 100 ml)			\$0.0124	C H 1%	
Antiseptic soln 10% (pack size greater than 15 ml but less than or equal to 100 ml)			\$0.0128 *	C H 1%	
Skin preparation, povidone iodine 10% with 30% alcohol (pack size 100 ml or less)			\$0.0163 *	C H 1%	
Skin preparation, povidone iodine 10% with 30% alcohol (pack size greater than 100 ml)			\$0.0200	C H 1%	
Skin preparation, povidone iodine 10% with 70% alcohol (pack size 100 ml or less)			\$0.0163 *	C H 1%	
Skin preparation, povidone iodine 10% with 70% alcohol (pack size greater than 100 ml)			\$0.0163 *	C H 1%	
Tretinoin					
<u>Cr</u> m 0.5 mg per g	1,126,400	\$313,139	\$0.2780	C H 1%	

Genito Urinary System

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Chlorhexidine gluconate					
<u>Cr</u> m 1% obstetric				H 1%	Preference for a small tube for single use, under 100 g. For disinfection and lubrication purposes in the gynaecology and obstetric specialities.
<u>Lot</u> n 1% obstetric				H 1%	For antiseptic purposes in gynaecology and obstetric specialities
Intra-Uterine Device					
IUD 29.1 mm length x 23.2 mm width	2,446	\$77,294	\$31.6000	C H 1%	
IUD 33.6 mm length x 29.9 mm width	6,015	\$190,074	\$31.6000	C H 1%	
IUD 35.5 mm length x 19.6 mm width	3,853	\$121,755	\$31.6000	C H 1%	
Norethisterone					
<u>Tab</u> 350 mcg	11,593,988	\$862,593	\$0.0744	C H 1%	
Oxytocin					
<u>Inj</u> 5 iu per ml, 1 ml	1,560	\$1,257	\$0.8060	C H 1%	
<u>Inj</u> 10 iu per ml, 1 ml	5,898	\$5,933	\$1.0060	C H 1%	
<u>Inj</u> 5 iu with ergometrine maleate 500 mcg per ml, 1 ml	2,922	\$6,504	\$2.2260	C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Genito Urinary System

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Potassium citrate						
Tab 99 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions.	
Oral liq 3 mmol per ml	428,400	\$64,260	\$0.1500	C H 1%	Special Authority restrictions may apply.	
Solifenacin succinate (current access)						
Tab 5 mg	3,110,408	\$3,888,010	\$1.2500 #	C H 1%	A confidential rebate applies. Special Authority restrictions may apply. PHARMAC would only award a tender for either current access or widened access.	
Tab 10 mg	753,088	\$941,360	\$1.2500 #	C H 1%	A confidential rebate applies. Special Authority restrictions may apply. PHARMAC would only award a tender for either current access or widened access.	
Solifenacin succinate (widened access)						
Tab 10 mg				C H 1%	PHARMAC would only award a tender for either current access or widened access.	
Tab 5 mg				C H 1%	PHARMAC would only award a tender for either current access or widened access.	

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Cabergoline						
Tab 0.5 mg (2 pack)	14,647	\$34,787	\$2.3750	C H 1%		
Tab 0.5 mg (8 pack)	55,099	\$130,860	\$2.3750	C H 1%		
Calcitonin						
Inj 100 iu per ml, 1 ml	205	\$4,961	\$24.2000	C H 1%		
Cinacalcet						
Tab 30 mg	18,330	\$264,279	\$14.4179	C H 1%	Special Authority restrictions may apply.	
Cyproterone Acetate						
Tab 50 mg	694,521	\$220,441	\$0.3174	C H 1%		
Tab 100 mg	65,222	\$39,655	\$0.6080	C H 1%		
Dexamethasone						
Tab 0.5 mg - 1 mg	530,791	\$155,681	\$0.2933	C H 1%	0.5 mg tablet units and subsidy shown.	
Tab 4 mg	885,475	\$54,306	\$0.0613	C H 1%		
Ethinylloestradiol						
Tab 10 mcg	205,008	\$36,081	\$0.1760	C H 1%		
Hydrocortisone						
Tab 5 mg	3,330,859	\$269,800	\$0.0810	C H 1%		
Tab 20 mg	110,429	\$22,439	\$0.2032	C H 1%		
Methylprednisolone						
Tab 4 mg	15,363	\$12,290	\$0.8000	C H 1%		
Tab 100 mg	19,440	\$174,956	\$9.0000	C H 1%		
Methylprednisolone Acetate						
Inj 40 mg per ml, 1 ml	2,727	\$21,816	\$8.0000	C H 1%		
Methylprednisolone Acetate with Lignocaine						
Inj 40 mg per ml with lignocaine 1 ml	2,021	\$18,694	\$9.2500	C H 1%		
Methylprednisolone Sodium Succinate						
Inj 40 mg per ml, 1 ml	546	\$5,733	\$10.5000	C H 1%		
Inj 62.5 mg per ml, 2 ml	177	\$3,938	\$22.2500	C H 1%		
Inj 500 mg	110	\$988	\$9.0000	C H 1%		
Inj 1 g	135	\$2,160	\$16.0000	C H 1%		
Norethisterone						
Tab 5 mg	1,445,661	\$264,411	\$0.1829	C H 1%		

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Oestradiol valerate						
Tab 1 mg	1,441,200	\$212,058	\$0.1471	C H 1%		
Tab 2 mg	1,657,296	\$243,855	\$0.1471	C H 1%		
Prednisolone						
Oral liq 5 mg per ml	3,706,110	\$926,528	\$0.2500	C H 1%	Preference for packsize <50 ml. Special Authority criteria may apply.	
Somatropin						
Inj 0.05 mg per - 2.5 mg per ml, including overage				C H 1%	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all presentations of somatropin. Preference for suppliers who can provide multiple presentations of somatropin. Refer to Schedule 7 for additional Terms	
Inj 2.51 mg per ml - 5.5 mg per ml, including overage	3,120	\$341,640	\$109.5000 #	C H 1%	PHARMAC reserves the right to award one, some or all presentations of somatropin. Preference for suppliers who can provide multiple presentations of somatropin. May be subject to SA restrictions. Refer to Schedule 7 for additional Special Terms.	
Inj 5.51 mg per ml - 9 mg per ml, including overage	5,467	\$1,197,273	\$219.0000 #	C H 1%	PHARMAC reserves the right to award one, some or all presentations of somatropin. Preference for suppliers who can provide multiple presentations of somatropin. May be subject to SA restrictions. Refer to Schedule 7 for additional Special Terms.	
Inj 9.01 mg ml or greater, including overage	3,455	\$1,134,968	\$328.5000 #	C H 1%	PHARMAC reserves the right to award one, some or all presentations of somatropin. Preference for suppliers who can provide multiple presentations of somatropin. May be subject to SA restrictions. Refer to Schedule 7 for additional Special Terms.	
Terlipressin acetate						
Inj 1 mg				H 1%		
Testosterone						
Transdermal patch 2.5 mg	134,512	\$179,349	\$1.3333	C H 1%		
Transdermal patch 5 mg	60	\$160	\$2.6667	C H 1%		
Testosterone undecanoate						
Cap 40 mg	139,088	\$38,945	\$0.2800	C H 1%		
Zoledronic Acid						
Inj 4 mg per 5 ml	1,216	\$102,752	\$84.5000	C H 1%	May be subject to Special Authority criteria. Two brands are currently listed in the Pharmaceutical Schedule, subsidy shown is for the lower of the two.	

Infections

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Aciclovir						
Inj 250 mg				H 1%		
Amikacin						
Inj 250 mg per ml, 2 ml				H 1%	Preference for syringes	
Amoxicillin clavulanate						
Inj 500 mg with clavulanic acid 100 mg				H 1%		
Inj 1000 mg with clavulanic acid 200 mg				H 1%		
Amphotericin B						
Liposomal inj 50 mg				H 1%		

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Atovaquone with proguanil hydrochloride							
Tab 250 mg with proguanil hydrochloride 100 mg					H 1%	Preference for a pack size of one treatment course.	
Tab 62.5mg with proguanil hydrochloride 25 mg (Paediatric)					H 1%	Preference for a pack size of one treatment course.	
Azithromycin							
<u>Grans for oral liq 200 mg per 5 ml</u>	96,000	\$80,000	\$0.8333		C H 1%		
<u>Tab 250 mg</u>	62,661	\$18,798	\$0.3000		C H 1%		
<u>Tab 500 mg</u>	179,779	\$94,384	\$0.5250		C H 1%		
Benzathine Benzylpenicillin							
<u>Inj 1.2 mega u</u>	9,575	\$301,613	\$31.5000	@	C H 1%	Additional Stock Pharmaceutical.	
Cefepime Hydrochloride							
Inj 1 g					H 1%		
Inj 2 g					H 1%		
Cefoxitin Sodium							
Inj 1 g					H 1%		
Ceftazidime							
Inj 500 mg					H 1%		
Cephalexin Monohydrate							
<u>Grans for oral liq 125 mg per 5 ml</u>	2,228,444	\$178,276	\$0.0800		C H 1%		
<u>Grans for oral liq 250 mg per 5 ml</u>	7,141,060	\$785,517	\$0.1100		C H 1%		
Chloramphenicol							
Inj 1 g					H 1%		
Cidofovir							
Inj 75 mg per ml, 5 ml					H 1%		
Ciprofloxacin							
Inj 2 mg per ml, 100 ml					H 1%		
Daptomycin							
Inj 500 mg vial					H 1%		
Inj 350 mg vial					H 1%		
Efavirenz							
Oral liq 30 mg per ml			\$0.8099		C H 1%	Special Authority restrictions may apply.	
<u>Tab 50 mg</u>	1,008	\$2,130	\$2.1127		C H 1%	Special Authority restrictions may apply.	
<u>Tab 200 mg</u>	6,684	\$14,122	\$2.1128		C H 1%	Special Authority restrictions may apply.	
<u>Tab 600 mg</u>	50,380	\$106,436	\$2.1127		C H 1%	Special Authority restrictions may apply.	
Flucloxacillin							
<u>Grans for oral liq 125 mg per 5 ml</u>	2,641,938	\$60,516	\$0.0229		C H 1%	Bids would be accepted for either the sodium or magnesium salts.	
<u>Grans for oral liq 250 mg per 5 ml</u>	5,274,035	\$162,471	\$0.0308		C H 1%	Bids would be accepted for either the sodium or magnesium salts.	
Flucloxacillin sodium							
<u>Cap 250 mg</u>	988,495	\$73,939	\$0.0748		C H 1%		
<u>Cap 500 mg</u>	10,742,569	\$1,351,415	\$0.1258		C H 1%		
Fosfomycin							
Powder for oral solution, 3 g sachet					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions.	
Gentamicin Sulphate							
Inj 10 mg per ml, 1 ml	1,087	\$1,861	\$1.7120		C H 1%		
Inj 10 mg per ml, 2 ml			\$7.0040		C H 1%		
<u>Inj 40 mg per ml, 2 ml</u>	12,155	\$7,293	\$0.6000		C H 1%		
Imipenem with cilastatin							
Inj 500 mg with cilastatin 500 mg					H 1%		

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Isoniazid					
<u>Tab 100 mg</u>	174,052	\$34,810	\$0.2000	C H 1%	
Isoniazid with rifampicin					
<u>Tab 100 mg with rifampicin 150 mg</u>	20,818	\$17,808	\$0.8554	C H 1%	
<u>Tab 150 mg with rifampicin 300 mg</u>	124,020	\$211,578	\$1.7060	C H 1%	
Linezolid					
Inj 2 mg per ml, 300 ml				H 1%	
Oral liq 20 mg per ml				H 1%	
Tab 600 mg				H 1%	
Lopinavir with ritonavir					
Tab 100 mg with ritonavir 25 mg	3,060	\$9,371	\$3.0625	C H 1%	Special Authority restrictions may apply.
Oral liq 80 mg with ritonavir 20 mg per ml			\$2.4500	C H 1%	Special Authority restrictions may apply.
Mefloquine hydrochloride					
Tab 250 mg				H 1%	
Metronidazole					
Oral liq benzoate 200 mg per 5 ml	589,259	\$147,315	\$0.2500	C H 1%	
Suppos 500 mg	4,588	\$11,231	\$2.4480	C H 1%	
Tab 200 mg	783,324	\$81,857	\$0.1045	C H 1%	
Tab 400 mg	1,559,245	\$283,003	\$0.1815	C H 1%	
Nevirapine					
<u>Tab 200 mg</u>	158,134	\$171,311	\$1.0833	C H 1%	
Phenoxymethylpenicillin (Penicillin V)					
<u>Cap 250 mg</u>	330,008	\$19,008	\$0.0576	C H 1%	
<u>Cap 500 mg</u>	1,979,192	\$187,232	\$0.0946	C H 1%	
Teicoplanin					
Inj 400 mg				H 1%	
Ticarcillin with clavulanic acid					
Inj 3 g with clavulanic acid 0.1 mg vial				H 1%	
Tobramycin					
<u>Inj 40 mg per ml, 2 ml</u>	3,488	\$10,464	\$3.0000 #	C H 1%	A confidential rebate applies.
Powder BP				H 1%	
Solution for inhalation 60 mg per ml, 5 ml	21,074	\$827,907	\$39.2857 #	C H 1%	A confidential rebate applies.
Inj 100 mg per ml, 5 ml				H 1%	
Trimethoprim					
Tab 100 mg				H 1%	
<u>Tab 300 mg</u>	1,432,450	\$429,735	\$0.3000	C H 1%	
Trimethoprim with sulphamethoxazole [Co-trimoxazole]					
Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	3,466,265	\$158,755	\$0.0458	C H 1%	
Valaciclovir					
Tab 1000 mg	91,556	\$38,911	\$0.4250	C H 1%	
<u>Tab 500 mg</u>	782,040	\$167,356	\$0.2140	C H 1%	
Valganciclovir					
<u>Tab 450 mg</u>	44,598	\$780,465	\$17.5000	+ C H 1%	Access may be widened depending on price.
Voriconazole					
Powder for oral suspension 40 mg per ml	770	\$9,636	\$12.5143	C H 1%	Special Authority restrictions may apply.
<u>Tab 200 mg</u>	12,115	\$108,170	\$8.9286	C H 1%	
<u>Tab 50 mg</u>	6,220	\$14,439	\$2.3214	C H 1%	
Zidovudine [AZT]					
Inj 10 mg per ml, 20 ml vial			\$150.0000	C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Musculoskeletal System

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments
Atracurium Besylate						
Inj 10 mg per ml, 2.5 ml					H 1%	
Inj 10 mg per ml, 5 ml					H 1%	
Baclofen						
<u>Inj 0.05 mg per ml, 1 ml</u>			\$11.5500		C H 1%	
Inj 2 mg per ml, 5 ml	204	\$42,695	\$209.2900		C H 1%	
Oral liq 1 mg per ml					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Tab 10 mg	4,631,056	\$178,296	\$0.0385		C H 1%	
Colchicine						
Tab 500 mcg	4,096,211	\$412,898	\$0.1008		C H 1%	
Dantrolene Sodium						
Inj 20 mg					H 1%	
Cap 25 mg	108,455	\$70,496	\$0.6500		C H 1%	
Cap 50 mg	42,629	\$32,824	\$0.7700		C H 1%	
Diclofenac sodium						
Inj 25 mg per ml, 3 ml	24,301	\$64,155	\$2.6400		C H 1%	
Suppos 12.5 mg	6,023	\$1,229	\$0.2040		C H 1%	
<u>Tab EC 25 mg</u>	679,269	\$17,661	\$0.0260		C H 1%	
Suppos 25 mg	5,637	\$1,375	\$0.2440		C H 1%	
<u>Tab EC 50 mg</u>	3,346,357	\$66,927	\$0.0200		C H 1%	
Suppos 50 mg	74,182	\$31,305	\$0.4220		C H 1%	
<u>Tab long-acting 75 mg</u>	19,021,892	\$578,266	\$0.0304		C H 1%	
Suppos 100 mg	114,724	\$80,307	\$0.7000		C H 1%	
<u>Tab long-acting 100 mg</u>	1,796,234	\$94,123	\$0.0524		C H 1%	
Etidronate Disodium						
<u>Tab 200 mg</u>	153,283	\$20,693	\$0.1350		C H 1%	
Hydroxychloroquine Sulphate						
<u>Tab 200 mg</u>	3,954,266	\$415,198	\$0.1050		C H 1%	
Ibuprofen						
Oral liq 20 mg per ml	50,539,579	\$477,599	\$0.0095		C H 1%	Preference for a 200 ml bottle or similar.
<u>Tab long-acting 800 mg</u>	12,179,727	\$3,243,827	\$0.2663		C H 1%	
Indomethacin						
Inj 1 mg					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Cap 25 mg					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Cap 50 mg					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Cap long-acting 75 mg					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Suppos 100 mg					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Naproxen						
<u>Tab 250 mg</u>	3,856,975	\$139,314	\$0.0361		C H 1%	
<u>Tab long-acting 750 mg</u>	1,701,746	\$340,349	\$0.2000		C H 1%	
<u>Tab 500 mg</u>	7,594,401	\$574,440	\$0.0756		C H 1%	
<u>Tab long-acting 1,000 mg</u>	1,463,807	\$341,560	\$0.2333		C H 1%	
Orphenadrine Citrate						
Tab 100 mg	4,204,302	\$779,478	\$0.1854		C H 1%	
Teriparatide						
Inj 250 mcg per ml, 2.4 ml	1,898	\$930,020	\$490.0000#	+	C H 1%	Special Authority restrictions may apply.

Nervous System

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments
<u>sole supply</u>						

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Aprepitant					
Cap 2 x 80 mg and 1 x 125 mg	21,960	\$732,000	\$33.3333	C H 1%	Special Authority restrictions may apply.
Asenapine					
10 mg sublingual wafer				C H 1%	Not currently listed on the Pharmaceutical Schedule.
5 mg sublingual wafer				C H 1%	Not currently listed on the Pharmaceutical Schedule.
Bupivacaine hydrochloride					
Inj 0.25%, 20 ml				H 1%	
Inj 0.5%, 10 ml sterile pack				H 1%	
Inj 0.5%, 20 ml sterile pack				H 1%	
Bupirone hydrochloride					
Tab 5 mg	419,469	\$99,834	\$0.2380	C H 1%	
Tab 10 mg	523,991	\$78,389	\$0.1496	C H 1%	
Citalopram hydrobromide					
Tab 20 mg	32,339,716	\$689,159	\$0.0213	C H 1%	Tablets require a break line
Clomipramine Hydrochloride					
Tab 10 mg	253,761	\$31,974	\$0.1260	C H 1%	
Tab 25 mg	1,709,914	\$148,421	\$0.0868	C H 1%	
Cyclizine Hydrochloride					
Tab 50 mg	1,418,270	\$41,839	\$0.0295	C H 1%	
Dexamfetamine Sulphate					
Tab 5 mg	1,031,751	\$175,398	\$0.1700	C H 1%	
Domperidone					
Tab 10 mg	9,505,074	\$304,162	\$0.0320	C H 1%	
Entacapone					
Tab 200 mg	731,866	\$204,923	\$0.2800	C H 1%	
Fentanyl					
Inj 50 mcg per ml, 2 ml	232,401	\$91,798	\$0.3950	C H 1%	
Inj 50 mcg per ml, 10 ml	23,917	\$24,993	\$1.0450	C H 1%	
Haloperidol decanoate					
Inj 100 mg per ml, 1 ml ampoule	5,491	\$61,389	\$11.1800	C H 1%	
Inj 50 mg per ml, 1 ml ampoule	3,510	\$19,930	\$5.6780	C H 1%	
Ketamine					
Inj 100 mg per ml, 2 ml vial				H 1%	
Lacosamide					
Inj 10 mg per ml, 20 ml				H 1%	May be subject to restrictions.
Levomepromazine					
Tab 100 mg	89,491	\$39,340	\$0.4396	C H 1%	Preference for a scored tablet.
Tab 25 mg	516,465	\$87,438	\$0.1693	C H 1%	Preference for a scored tablet.
Lidocaine [Lignocaine] Hydrochloride					
Gel 2%				H 1%	Tender is for topical gel, not urethral syringe
Lidocaine [lignocaine] hydrochloride with adrenaline					
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge				H 1%	
Lithium carbonate					
Cap 250 mg	1,883,773	\$177,451	\$0.0942	C H 1%	
Tab 250 mg	1,542,294	\$105,801	\$0.0686	C H 1%	
Tab 400 mg	336,980	\$43,235	\$0.1283	C H 1%	
Lorazepam					
Tab 1 mg	6,398,460	\$276,158	\$0.0432	C H 1%	
Tab 2.5 mg	277,576	\$38,528	\$0.1388	C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System					
Chemical Name					
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Methadone hydrochloride					
Inj 10 mg per ml, 1 ml	28,524	\$173,996	\$6.1000	C H 1%	
<u>Oral liq 2 mg per ml</u>	1,534,113	\$42,572	\$0.0278	C H 1%	Preference for excipient-free products.
<u>Oral liq 5 mg per ml</u>	20,684,549	\$517,114	\$0.0250	C H 1%	Preference for excipient-free products.
<u>Tab 5 mg</u>	2,153,366	\$398,373	\$0.1850	C H 1%	
<u>Oral liq 10 mg per ml</u>	3,781,760	\$123,853	\$0.0328	C H 1%	Preference for excipient-free products.
Methylphenidate hydrochloride					
Cap modified-release 10 mg	191,499	\$99,579	\$0.5200	C H 1%	Special Authority restrictions may apply.
Cap modified-release 20 mg	381,315	\$259,294	\$0.6800	C H 1%	Special Authority restrictions may apply.
Cap modified-release 30 mg	316,937	\$269,609	\$0.8507	C H 1%	Special Authority restrictions may apply.
Cap modified-release 40 mg	274,339	\$279,826	\$1.0200	C H 1%	Special Authority restrictions may apply.
Tab extended-release 18 mg	294,758	\$579,297	\$1.9653 #	C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Tab extended-release 27 mg	274,682	\$599,198	\$2.1814 #	C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Tab extended-release 36 mg	612,008	\$1,467,393	\$2.3977 #	C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Tab extended-release 54 mg	515,741	\$1,482,631	\$2.8748 #	C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Midazolam					
Inj 1 mg per ml, 5 ml				H 5%	
Inj 5 mg per ml, 3 ml				H 5%	
Mirtazapine					
<u>Tab 30 mg</u>	2,159,956	\$183,596	\$0.0850	C H 1%	
<u>Tab 45 mg</u>	850,945	\$92,183	\$0.1083	C H 1%	
Moclobemide					
<u>Tab 150 mg</u>	928,382	\$158,011	\$0.1702	C H 1%	
<u>Tab 300 mg</u>	236,329	\$72,553	\$0.3070	C H 1%	
Modafinil (current access)					
Tab 100 mg	96,264	\$232,638	\$2.4167	C H 1%	May be subject to Special Authority criteria. PHARMAC would only award a tender for either current or widened access.
Modafinil (widened access)					
Tab 100 mg				C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would be to allow access to modafinil as a first-line treatment for hypersomnia associated with narcolepsy.
Morphine Hydrochloride					
<u>Oral liq 1 mg per ml</u>	8,460,377	\$373,949	\$0.0442	C H 1%	Preference for excipient-free products. Preference for products with child-resistant packaging.
<u>Oral liq 2 mg per ml</u>	392,750	\$27,493	\$0.0700	C H 1%	Preference for excipient-free products. Preference for products with child-resistant packaging.
<u>Oral liq 5 mg per ml</u>	649,218	\$58,430	\$0.0900	C H 1%	Preference for excipient-free products. Preference for products with child-resistant packaging.
<u>Oral liq 10 mg per ml</u>	358,880	\$46,654	\$0.1300	C H 1%	Preference for excipient-free products. Preference for products with child-resistant packaging.
Nitrazepam					
Tab 5 mg	427,882	\$22,335	\$0.0522	C H 1%	
Oxycodone hydrochloride					
<u>Inj 50 mg per ml</u>	36,687	\$374,207	\$10.2000	C H 1%	
<u>Cap 5 mg</u>	1,970,189	\$195,049	\$0.0990	C H 1%	Preference for products with child-resistant packaging.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Oxycodone hydrochloride					
<u>Cap 10 mg</u>	1,299,382	\$254,029	\$0.1955	C H 1%	Preference for products with child-resistant packaging.
<u>Cap 20 mg</u>	548,087	\$187,446	\$0.3420	C H 1%	Preference for products with child-resistant packaging.
<u>Inj 10 mg per ml, 1 ml</u>	43,214	\$74,070	\$1.7140	C H 1%	
<u>Inj 10 mg per ml, 2 ml</u>	29,193	\$98,612	\$3.3780	C H 1%	
<u>Tab controlled-release 5 mg</u>	1,166,662	\$153,416	\$0.1315	C H 1%	Preference for products with child-resistant packaging.
<u>Tab controlled-release 10 mg</u>	1,692,631	\$233,583	\$0.1380	C H 1%	Preference for products with child-resistant packaging.
<u>Tab controlled-release 20 mg</u>	1,130,179	\$266,722	\$0.2360	C H 1%	Preference for products with child-resistant packaging.
<u>Tab controlled-release 40 mg</u>	327,719	\$126,008	\$0.3845	C H 1%	Preference for products with child-resistant packaging.
<u>Tab controlled-release 80 mg</u>	105,251	\$74,254	\$0.7055	C H 1%	Preference for products with child-resistant packaging.
Paliperidone					
Inj 100 mg syringe	10,297	\$4,480,431	\$435.1200 #	+ C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Inj 150 mg syringe	10,463	\$4,552,661	\$435.1200 #	+ C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Inj 25 mg syringe	660	\$128,205	\$194.2500 #	+ C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Inj 50 mg syringe	1,979	\$538,189	\$271.9500 #	+ C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Inj 75 mg syringe	3,821	\$1,365,702	\$357.4200 #	+ C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Paracetamol					
Tab soluble 500 mg				H 1%	
<u>Suppos 125 mg</u>	69,843	\$25,772	\$0.3690	C H 1%	
<u>Suppos 250 mg</u>	40,340	\$15,289	\$0.3790	C H 1%	
<u>Suppos 500 mg</u>	110,172	\$27,763	\$0.2520	C H 1%	
Pethidine hydrochloride					
<u>Tab 50 mg</u>	159,456	\$71,117	\$0.4460	C H 1%	Preference for products with child-resistant packaging.
<u>Tab 100 mg</u>	57,914	\$36,196	\$0.6250	C H 1%	Preference for products with child-resistant packaging.
Phenobarbitone					
<u>Tab 15 mg</u>	71,633	\$4,298	\$0.0600	C H 1%	
<u>Tab 30 mg</u>	510,841	\$31,672	\$0.0620	C H 1%	
Phenytoin Sodium					
<u>Inj 50 mg per ml, 2 ml</u>	1,350	\$23,930	\$17.7260	C H 1%	
<u>Inj 50 mg per ml, 5 ml</u>	746	\$19,981	\$26.7840	C H 1%	
Pizotifen					
<u>Tab 500 mcg</u>	1,271,404	\$295,093	\$0.2321	C H 1%	
Riluzole					
Tab 50 mg	41,729	\$298,064	\$7.1429 #	C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Risperidone					
Inj 25 mg per 2 ml	5,794	\$787,868	\$135.9800	C H 1%	Depot injection. Special Authority restrictions may apply.
Inj 37.5 mg per 2 ml	7,529	\$1,345,508	\$178.7100	C H 1%	Depot injection. Special Authority restrictions may apply.
Inj 50 mg per 2 ml	10,117	\$2,201,055	\$217.5600	C H 1%	Depot injection. Special Authority restrictions may apply.
Rivastigmine					
Patch 4.6 mg per 24 hour	42,664	\$127,992	\$3.0000 #	+ C H 1%	Special Authority restrictions may apply. A confidential rebate applies.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Rivastigmine Patch 9.5 mg per 24 hour	50,138	\$150,414	\$3.0000 #	+	C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Sodium valproate Inj 400 mg per 4 ml					H 1%	
Tropisetron Inj 1 mg per ml, 2 ml Inj 1 mg per ml, 5 ml					H 1% H 1%	
Varenicline tartrate (current access) Tab 0.5 mg x 11 and 1 mg x 14 Tab 1 mg	587,900 2,148,327	\$1,422,248 \$5,197,426	\$2.4192 \$2.4193	+	C H 1% C H 1%	Special Authority restrictions may apply. PHARMAC would only award a tender for current or widened access. Special Authority restrictions may apply. PHARMAC would only award a tender for current or widened access.
Varenicline tartrate (widened access) Tab 0.5 mg x 11 and 1 mg x 14 Tab 1 mg					C H 1% C H 1%	PHARMAC would only award a tender for current or widened access. PHARMAC would only award a tender for current or widened access.
Ziprasidone Cap 20 mg Cap 40 mg Cap 60 mg Cap 80 mg	142,132 88,443 22,242 40,012	\$34,491 \$36,483 \$12,556 \$26,501	\$0.2427 \$0.4125 \$0.5645 \$0.6623		C H 1% C H 1% C H 1% C H 1%	
Zopiclone Tab 3.75 mg (pack size greater than 30 tablets) Tab 3.75 mg (pack size of 30 tablets or less) Tab 7.5 mg (pack size of 30 tablets or less) <u>Tab 7.5 mg (pack size greater than 30 tablets)</u>					C H 1% H 1% H 1% C H 1%	Not currently listed on the Pharmaceutical Schedule. Not currently listed on the Pharmaceutical Schedule. Tablets should be scored. Tablets should be scored.

Oncology Agents and Immunosuppressants

Chemical Name Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Abiraterone acetate Tab 250 mg	523,015	\$18,637,598	\$35.6349 #	+	C H 1%	Special Authority restrictions may apply. A confidential rebate applies.
Azacitidine Inj 100 mg			#	PCT	H 1%	A confidential rebate currently applies.
Bleomycin Sulphate Inj 15,000 iu				PCT	H 1%	
Calcium folinate Inj 3 mg per ml, 1 ml Inj 300 mg - 350 mg			\$3.4200 \$89,995		PCT C H 1% PCT C H 1%	Units and subsidy shown are per 300 mg injection
Carboplatin Inj 10 mg per ml, 5 ml Inj 10 mg per ml, 15 ml Inj 10 mg per ml, 45 ml					PCT H 1% PCT H 1% PCT H 1%	
Carmustine Inj 100 mg				PCT	H 1%	
Ciclosporin Inf 50 mg per ml, 5 ml					H 1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Oncology Agents and Immunosuppressants

Chemical Name	Units	Cost	Unit Subsidy	DV	Limit	Comments
Line Item						
Cisplatin						
Inj 1 mg per ml, 100 ml				PCT H	1%	
Inj 1 mg per ml, 50 ml				PCT H	1%	
Cyclophosphamide						
Inj 1 g				PCT C H	1%	
Inj 2 g				PCT H	1%	
Tab 50 mg	137,682	\$217,538	\$1.5800	PCT C H	1%	
Doxorubicin						
Inj 100 mg				PCT H	1%	
Inj 200 mg				PCT H	1%	
Doxorubicin Hydrochloride						
Inj 2 mg per ml, 5 ml				PCT H	1%	
Epirubicin						
Inj 2 mg per ml, 5 ml				PCT H	1%	
Inj 2 mg per ml, 25 ml				PCT H	1%	
Inj 2 mg per ml, 50 ml				PCT H	1%	
Inj 2 mg per ml, 100 ml				PCT H	1%	
Erlotinib hydrochloride						
Tab 100 mg	8,027	\$204,421	\$25.4667	+ C H	1%	
Tab 150 mg	22,078	\$843,380	\$38.2000	+ C H	1%	
Etoposide						
<u>Inj 20 mg per ml, 5 ml</u>		\$47,626	\$7.9000	PCT C H	1%	
Fludarabine phosphate						
<u>Tab 10 mg</u>	9,428	\$194,217	\$20.6000	PCT C H	1%	
Fluorouracil sodium						
Inj 50 mg per ml, 20 ml				PCT H	1%	
Inj 50 mg per ml, 50 ml				PCT H	1%	
Inj 50 mg per ml, 100 ml				PCT H	1%	
Idarubicin Hydrochloride						
Inj 5 mg				PCT H	1%	
Inj 10 mg				PCT H	1%	
Irinotecan						
Inj 20 mg per ml, 2 ml				PCT H	1%	
Inj 20 mg per ml, 5 ml				PCT H	1%	
Letrozole						
<u>Tab 2.5 mg</u>	1,000,343	\$98,364	\$0.0983	C H	1%	
Lomustine						
Cap 10 mg	691	\$4,581	\$6.6295	PCT C H	1%	
Cap 40 mg	575	\$11,476	\$19.9575	PCT C H	1%	
Megestrol Acetate						
<u>Tab 160 mg</u>	32,528	\$58,876	\$1.8100	C H	1%	
Methotrexate						
Inj 100 mg per ml, 10 ml			\$25.0000	PCT C H	1%	
Inj 2.5 mg per ml, 2 ml		\$7,427	\$4.7300	PCT C H	1%	
Inj 7.5 mg prefilled syringe	859	\$12,550	\$14.6100	C H	1%	
Inj 10 mg prefilled syringe	7,387	\$108,293	\$14.6600	C H	1%	
Inj 15 mg prefilled syringe	8,755	\$129,311	\$14.7700	C H	1%	
<u>Tab 2.5 mg</u>	1,460,422	\$154,805	\$0.1060	PCT C H	1%	
Inj 20 mg prefilled syringe	17,183	\$255,683	\$14.8800	C H	1%	
<u>Tab 10 mg</u>	951,674	\$399,703	\$0.4200	PCT C H	1%	
Inj 25 mg prefilled syringe	6,199	\$92,923	\$14.9900	C H	1%	
Inj 30 mg prefilled syringe	296	\$4,467	\$15.0900	C H	1%	
Mitozantrone						
Inj 2 mg per ml, 10 ml				PCT H	1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Oncology Agents and Immunosuppressants

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Oxaliplatin					
Inj 50 mg				PCT H 1%	
Inj 100 mg				PCT H 1%	
Paclitaxel					
Inj 150 mg				PCT H 1%	
Inj 600 mg				PCT H 1%	
Vinorelbine					
Inj 10 mg per ml, 1 ml				PCT H 1%	
Inj 10 mg per ml, 5 ml				PCT H 1%	

Respiratory System and Allergies

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Dextrochlorpheniramine Maleate					
Oral liq 2 mg per 5 ml	14,820	\$262	\$0.0177 *	C H 1%	
Tab 2 mg	158,812	\$8,020	\$0.0505 *	C H 1%	
Fexofenadine Hydrochloride					
Tab 120 mg	107,327	\$50,869	\$0.4740	C H 1%	
Tab 180 mg				C H 1%	Not currently listed on Pharmaceutical Schedule
Tab 60 mg	39,888	\$8,656	\$0.2170 *	C H 1%	
Fluticasone propionate					
<u>Metered aqueous nasal spray, 50 mcg per dose</u>	80,156,160	\$1,456,437	\$0.0182	C H 1%	
Promethazine Hydrochloride					
<u>Oral liq 5 mg per 5 ml</u>	3,631,768	\$94,063	\$0.0259	C H 1%	
<u>Tab 10 mg</u>	1,871,837	\$66,637	\$0.0356	C H 1%	
<u>Tab 25 mg</u>	2,480,741	\$98,733	\$0.0398	C H 1%	
Salbutamol					
<u>Nebuliser soln, 1 mg per ml, 2.5 ml</u>	283,418	\$45,205	\$0.1595	C H 1%	
<u>Nebuliser soln, 2 mg per ml, 2.5 ml</u>	569,447	\$93,674	\$0.1645	C H 1%	
Salbutamol with Ipratropium Bromide					
<u>Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml</u>	458,271	\$82,260	\$0.1795	C H 1%	

Sensory Organs

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Bimatoprost					
<u>Eye Drops 0.03%</u>	270,693	\$329,344	\$1.2167	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK/preservative free product for a restricted market.
Ciprofloxacin with Hydrocortisone					
Ear drops 0.2% with hydrocortisone 1%				H 1%	
Diclofenac Sodium					
Eye drops 0.1%	123,085	\$339,715	\$2.7600	C H 1%	
Dorzolamide hydrochloride					
Eye drops 2%	11,800	\$23,057	\$1.9540 *	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml
Dorzolamide hydrochloride with timolol maleate					
<u>Eye drops 2% with timolol maleate 0.5%</u>	394,725	\$272,360	\$0.6900	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Unit subsidy expressed as "per ml"

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Sensory Organs

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments
Hypromellose						
Eye drops 0.5%	54,645	\$7,286	\$0.1333 *		C H 1%	
Eye drops 0.3% with dextran	2,884,320	\$442,253	\$0.1533		C H 1%	
Latanoprost						
<u>Eye drops 50 mcg per ml</u>	783,225	\$469,935	\$0.6000		C H 1%	Unit subsidy expressed as "per ml".For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market
Levocabastine						
Eye drops 0.5 mg per ml	101,036	\$220,006	\$2.1775 *		C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml
Lodoxamide						
Eye drops 0.1%	270,570	\$235,666	\$0.8710		C H 1%	
Mixed salt solution for eye irrigation						
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 15 ml - 20 ml					H 1%	
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 200 ml - 300 ml					H 1%	
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 450 ml - 550 ml					H 1%	
Paraffin liquid with wool fat liquid						
Eye oint 3% with wool fat liq 3%	82,002	\$85,047	\$1.0371		C H 1%	
Pilocarpine hydrochloride						
<u>Eye drops 1%</u>	15,540	\$4,413	\$0.2840		C H 1%	
<u>Eye drops 2%</u>	40,260	\$14,359	\$0.3567		C H 1%	
Eye drops 2% single dose	160	\$256	\$1.5975		C H 1%	
<u>Eye drops 4%</u>	28,350	\$15,101	\$0.5327		C H 1%	

Various

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments
Acetylcysteine						
Inj 200 mg per ml	2,511	\$19,671	\$7.8340		C H 1%	
Desferrioxamine mesilate						
<u>Inj 500 mg</u>	7,570	\$39,001	\$5.1520		C H 1%	Preference for products where stability data >48 hours post-compounding
Flumazenil						
Inj 0.1 mg per ml, 5 ml					H 1%	
Naloxone Hydrochloride						
Inj 400 mcg per ml, 1 ml	8,931	\$87,238	\$9.7680		C H 1%	
Povidone Iodine						
Oint 10%			\$0.1308		C H 1%	